# Lead4Life

**Funder:** KWF
**Budget:** €0.5-2M PPP subsidy per project (total project budget €0.8-3.3M)
**Deadline:** 22 September 2026 (12:00 noon; full proposal deadline)
**Duration:** Up to 4 years
**Consortium:** Required — public-private partnership consortium including private party, per Health~Holland PPP requirements; Consortium Agreement between all participants mandatory
**Application:** 2-stage: matchmaking phase → full-proposal phase
**Frequency:** One-off
**Eligible countries:** NL
**Official call:** https://www.kwf.nl/en/forresearchers/funding/lead4life
**Last updated:** 6 Sept 2026

## Eligibility & scope

Health~Holland PPP call for production technology of medical isotope lead-212 and enabling clinical technologies, run jointly by KWF, NRG PALLAS, FAST and Oncode Institute; requires PPP consortium with private party and Consortium Agreement, Dutch summary reviewed by Patient Advisory Committee.

## Summary

The KWF Lead4Life grant funds public, private partnerships developing lead-212 radiopharmaceuticals and enabling technologies for cancer treatment, with KWF contributing €0.5M-€2M per project over up to four years as part of a €5M joint call with NRG PALLAS, FAST, and Oncode Institute. Consortia must include industry partners and comply with Health~Holland PPP governance; proposals focus on Pb-212 production, supply-chain infrastructure, or clinical-translation pathways. This is a one-off call open to Dutch institutions; private co-investment is mandatory.

## Who should apply

- Academic or hospital research groups with oncology and radiopharmaceutical expertise
- Consortia including at least one private-sector partner with co-investment commitment
- Researchers and institutions based in the Netherlands
- Projects addressing lead-212 production, supply-chain, or clinical-introduction bottlenecks
- Teams ready to engage a Patient Advisory Committee on the Dutch-language lay summary

## Key dates

- Full-proposal deadline: 22 September 2026 at 12:00 noon CET
- Matchmaking phase precedes the formal application; check the KWF website for matchmaking dates and logistics
- Project duration: up to four years

## Tips for applicants

- Consortium composition is non-negotiable: a weak or uncommitted industry partner will sink an otherwise strong science proposal. Secure written co-investment commitments before drafting.
- Lead-212 supply and manufacturing logistics dominate the review; if your project is purely downstream clinical science without a credible supply-chain or production-readiness angle, it does not fit this call.
- The Patient Advisory Committee reviews the Dutch summary for clarity and relevance to patients; avoid jargon even in the lay section, KWF takes this step seriously.

## Frequently asked questions

### How much can I get from the KWF Lead4Life grant?

KWF contributes €0.5M-€2M per project; the consortium must secure additional private co-investment to reach the project budget.

### Do I need a private-sector partner to apply for Lead4Life?

Yes, Lead4Life is a mandatory public, private partnership; at least one industry partner with documented co-investment is required.

### What research does the KWF Lead4Life grant fund?

Projects on lead-212 radiopharmaceutical development, Pb-212 production and supply-chain infrastructure, or enabling technologies for clinical introduction in cancer treatment.

### Is the KWF Lead4Life grant open outside the Netherlands?

No, this is a one-off Dutch call; all consortium members must be based in the Netherlands and comply with Dutch Health~Holland PPP rules.

### What is the Lead4Life application process?

Two-stage: a matchmaking phase helps consortia form, followed by full-proposal submission by 22 September 2026.

---

Source: [The Great Grantsby](https://grantsby.eu/grants/kwf-lead4life-2026-09) — EU grant monitoring for academic researchers. Always verify details on the funder's website before applying.

**See which EU calls match your profile.** [Preview your matches in 30 seconds, no signup](https://grantsby.eu/demo?ref=llm_grant_md).